UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000051970 |
|---|---|
| Receipt number | R000059314 |
| Scientific Title | Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria) |
| Date of disclosure of the study information | 2023/08/25 |
| Last modified on | 2024/07/02 17:48:08 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria)
Acronym
Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria)
Scientific Title
Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria)
Scientific Title:Acronym
Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)(Chronic spontaneous urticaria)
Region
| Japan |
Condition
Condition
Prurigo nodularis, Chronic spontaneous urticaria
Classification by specialty
| Dermatology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To collect information on the safety and effectiveness of long-term administration of Dupilumab in patients with prurigo nodular not adequately controlled with existing therapies.
To collect information on the safety and effectiveness of long-term administration of Dupilumab in patients with chronic spontaneus urticaria not adequately controlled with existing therapies.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Safety:Incidence rates of adverse drug reactions, Safety specification items of Dupixent
Effectiveness (PN):Investigator's Global Assessment for PN-Stage(IGA PN-S), Investigator's Global Assessment for PN-Activity(IGA PN-A), Worst-itch numeric rating scale(WI-NRS)
Effectiveness (CSU): Investigator's Global Assessment
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
-Patients with prurigo nodular not adequately controlled with existing therapies or Patients with chrinic spontaneus urticaria not adequately controlled with existing therapies
-Patients who newly start receiving the treatment with Dupixent
-Patients who can provide informed consent (in parson or legal representative)
Key exclusion criteria
Subjects who are participating in or have been registered for clinical trials with therapeutic intervention to Dupixent
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | Masahiro |
| Middle name | |
| Last name | TAMURA |
Organization
Sanofi K.K.
Division name
Post-authorization regulatory studies, Medical Affairs
Zip code
163-1488
Address
3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo 163-1488, Japan
TEL
03-6301-3867
Sanofi_Medical@sanofi.com
Public contact
Name of contact person
| 1st name | Public contact for Drug use surveillance |
| Middle name | |
| Last name | - |
Organization
Sanofi K.K.
Division name
Post-authorization regulatory studies, Medical Affairs
Zip code
163-1488
Address
3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo 163-1488, Japan
TEL
03-6301-3867
Homepage URL
Sanofi_Medical@sanofi.com
Sponsor or person
Institute
Sanofi K.K.
Institute
Department
Personal name
Funding Source
Organization
Sanofi K.K.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Japan Conference of Clinical Research
Address
1-13-23 Minamiikebukuro Toshima-ku, Tokyo Japan
Tel
03-6868-7022
jccr-info@jccr.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 08 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2023 | Year | 07 | Month | 11 | Day |
Date of IRB
| 2023 | Year | 07 | Month | 21 | Day |
Anticipated trial start date
| 2023 | Year | 12 | Month | 23 | Day |
Last follow-up date
| 2026 | Year | 12 | Month | 27 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Observational study
Management information
Registered date
| 2023 | Year | 08 | Month | 22 | Day |
Last modified on
| 2024 | Year | 07 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059314
